The activities of cytosolic 3-hydroxy-3-methylglutaryl coenzyme A synthase [3-hydroxy-3-methylglutarylCoA acetoacetyl-CoA-lyase (CoA-acetylating), EC 4.1.3.5] and microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase Imevalonate:NADP+ oxidoreductase (CoA-acylating), EC
1.1.1.341, two sequential enzymes in the cholesterol biosynthetic pathway, were shown to be regulated coordinately in the adrenal gland of the rat. When the plasma cholesterol level was lowered by administration of 4-aminopyrazolopyrimidine, a treatment known to enhance cholesterol synthesis in the adrenal, synthase activity in the gland rose by 14-to 29 -fold and reductase activity rose by 50-to 100-fold. The subsequent intravenous infusion of low density lipoprotein restored the plasma cholesterol level and suppressed synthase and reductase activities in parallel. The activities of adrenal 3-hydroxy-3-methylglutaryl coenzyme A synthase and reductase were also shown to exhibit a coordinate pattern of diurnal variation with peaks in both enzymes achieved at the mid-point of the dark cycle. The activity of adrenal acetoacetyl coenzyme A thiolase (acetyl CoA acetyltransferase; acetyl-CoA:acetyl-CoA C-acetyltransferase, EC 2.3.1.9), the enzyme preceding the synthase in the cholesterol biosynthetic pathway, and the activity-of adrenal mevalonate kinase (ATP:mevalonate 5-phosphotransferase, EC 2.7.1.36), the enzyme following the reductase, were not enhanced by cholesterol deprivation, and neither exhibited a pattern of diurnal variation. The coordinate control of 3-hydroxy-3-methylglutaryl CoA synthase and reductase in rat adrenal gland provides a model system to study the biochemical mechanism for the regulation of cholesterol synthesis in a tissue that uses cholesterol for the synthesis of steroid hormones.
Recent studies have shown that cholesterol synthesis is subject to an extraordinary degree of regulation in the adrenal gland of the rat (1, 2) . When plasma cholesterol levels are normal, the adrenal gland satisfies its large requirement for cholesterol as a precursor for steroid hormone synthesis by utilizing the cholesterol contained in plasma lipoproteins (1) (2) (3) (4) (5) . However, when the availability of plasma cholesterol is diminished, such as when hepatic lipoprotein secretion is blocked by administration of the drug 4-aminopyrazolopyrimidine (4-APP) (6-9), cholesterol synthesis in the adrenal gland rises by as much as 30-fold (1, 2 (11, 12) (Fig. 1) . The situation in liver is complex, however, because HMG CoA is synthesized at two sites within this tissue (13) (14) (15) . The vast bulk of the HMG CoA is synthesized within the mitochondria by a specific intramitochondrial HMG CoA synthase (13) and is cleaved within the mitochondria by HMG CoA Iyase (EC 4.1.3.4) to produce acetoacetate (16) . A much smaller amount of hepatic HMG CoA is synthesized by a distinct HMG CoA synthase within the cytosol (13) . This cytosolic HMG CoA is reduced by microsomal HMG CoA reductase to form mevalonate, which is subsequently converted to cholesterol (Fig. 1) . The experiments of Lane and co-workers have shown that in liver the cytosolic but not the mitochondrial HMG CoA synthase is suppressed by cholesterol feeding (11, 12) .
The magnitude of the rise in the activity of HMG CoA reductase in the adrenal gland of the 4-APP-treated rat suggested the use of this tissue as a model system to determine whether a similar degree of regulation exists at the level of HMG CoA synthase. This model is particularly useful because the adrenal gland is not known to produce large amounts of ketone bodies and hence should Animals. Male Sprague-Dawley rats weighing between 300 and 400 g were obtained from Charles River Laboratories. Unless otherwise indicated, the rats were exposed to a light-dark cycle consisting of 12 hr of light (0700-1900 hr) and 12 hr of darkness for at least 2 weeks prior to use. Throughout these periods of adaptation, the rats had full access to water and formula chow (Wayne's Laboratory, Chicago).
In experiments in which 4-APP-treated rats were used, the animals were given daily injections of 4 for 3 days and were killed on the fourth day (2, 8) . For intravenous injection of low density lipoprotein, a polyethylene cannula was introduced into the tail vein while the animal was under light anesthesia. Control animals received appropriate volumes of either 10 mM sodium phosphate, pH 3, intraperitoneally for the 4-APP experiments or saline intravenously for the lipoprotein experiments.
Lipoproteins. Human low density lipoprotein (LDL) (density, 1.019-1.063 g/ml) was obtained from the plasma of healthy subjects as described previously (17) .
Preparation of Adrenal Cytosolic and Microsomal Fractions. Rats were routinely killed at 0900 hr by decapitation, and blood was collected by drainage from the neck into a tube containing EDTA. All subsequent steps were carried out at 4°. The adrenal glands were removed immediately, placed into ice-cold medium containing 0.3 M sucrose, 25 mM 2-mercaptoethanol, and 10 mM EDTA, pH 7, and homogenized as previously described (2) . The homogenate was subjected to centrifugation at 10,000 X g for 10 min and the resulting supernatant was spun at 100,000 X g for 1 hr. The pellet from this latter centrifugation (microsomal fraction) was washed once in the homogenizing buffer, frozen, and stored at -60°. The supernatant from the 100,000 X g centrifugation (cytosolic fraction) was dialyzed for 24 To confirm the identity of the reaction product, the nonvolatile 14C radioactivity was subjected to ascending paper chromatography using butanol/acetic acid/water (5:2:3, vol/ vol) as solvent. Authentic [14C]HMG CoA was also heated with 0.3 ml of 6 M HCO at 950 for 2 hr and subjected to chromatography simultaneously with the 14C-labeled reaction product. In both samples, two radioactive peaks were observed: a major peak with an RF of 0.8, which corresponded to HMG, and a minor peak with an RF of 0.6, whose identity was not determined. The relative proportions of the minor peak (35%) and the major peak (65%) were similar for the heated 14C-labeled reaction product and the heated authentic [14C]HMG CoA.
The identity of the 14C-labeled reaction product was further confirmed by the demonstration that it could be converted to
[14C]mevalonate in the presence of NADPH and microsomal HMG CoA reductase. For this experiment, a scaled-up HMG CoA synthase reaction was conducted, and the reaction was stopped by heating for 15 min at 500 to inactivate the HMG CoA synthase. One aliquot of this mixture was added to 6 M HCI and heated to determine the amount of nonvolatile 14C radioactivity. Another aliquot was added to a solution containing the reaction components for the HMG CoA reductase assay supplemented with adrenal microsomes from a 4-APPtreated rat. (The microsomes had been subjected to prior heating at 500 for 30 min to inactivate traces of adherent HMG CoA synthase.) The mixture was incubated at 370 and aliquots were removed at different times to determine the amount of
[14C]mevalonate formed (2) . Under these conditions, the maximal amount of [14C]mevalonate formed was equal to 80-90% of the value expected from the determination of nonvolatile "'C radioactivity.
Assay Rats were treated as indicated, adrenal glands from four rats were pooled, cytosolic and microsomal fractions were prepared, and enzyme activities were determined as described under Materials and Methods. Each value represents the average of duplicate assays. The total recovery of protein in the cytosolic and microsomal fractions was about 2-fold higher in the 4-APP-treated rats as compared to the control rats.
of corticosterone in rat plasma was measured iby direct radioimmunoassay (21) .
RESULTS
To establish optimal conditions for the assay for HMG CoA synthase activity, cytosolic extracts were prepared from the adrenal glands of rats that had been treated for 3 days with 4-APP. When these extracts were assayed immediately after preparation, the rate of [14C]HMG CoA formation was linear for less than 5 min and proportional to the amount of extract only when the total amount of protein in the assay was less than 30 gg. However, when enzyme activity was assayed after the extracts had been dialyzed against phosphate buffer for 24 hr, the reaction was linear with time up to 15 min ( Fig. 2A) and with amounts of enzyme up to at least 60,ug of protein (Fig.  2B) . A similar effect of dialysis has been observed by Clinkenbeard et al. for HMG CoA synthase in crude extracts of chicken liver and this has been attributed to the inactivation of contaminating HMG CoA lyase during the dialysis (12) . In preliminary experiments, when care was taken to ensure that only initial reaction rates were measured, it was possible to show that the actual amount of adrenal HMG CoA synthase activity was not changed by the dialysis, irrespective of whether the extracts were prepared from control or 4-APP-treated rats. In , and adrenal acetoacetyl CoA thiolase and mevalonate kinase activities (C) in rats previously treated with 4-APP. Five groups of rats (three rats per group) were treated with 4-APP for 3 days. Twelve hours after the last dose of 4-APP, four groups of rats received the indicated amount of human LDL intravenously as a bolus. The control group received an intravenous injection of 0.15 M NaCl. All the animals were killed 12 hr later (on the fourth day). Blood was collected, and the adrenal glands from the three rats in each group were excised and pooled for homogenization. All measurements were made as described under Materials and Methods. All assays were performed in duplicate. treated rats was found in the cytosolic fraction. No synthase activity could be detected in the mitochondrial fraction (10,000 X g pellet) even after a 24 hr dialysis of detergent-disrupted mitochondria (12) . In the same extracts, more than 90% of the marker enzyme glutamate dehydrogenase was found in the mitochondrial fraction.
When adrenal extracts were prepared from control rats, HMG CoA synthase activity was barely detectable (Fig. 3) . On the other hand, when rats had been treated for 3 days with 4-APP, a condition known to cause a marked decrease in plasma and adrenal cholesterol levels and a marked increase in adrenal cholesterol synthesis (1, 2), the activity of HMG CoA synthase was increased by more than 15-fold. The data in Fig. 3 show that mixing of the two types of cytosol preparations gave only additive activities. Hence, the difference in the enzyme activity between the 4-APP-treated and control rats was not due to the presence of enzyme inhibitors or activators. (C) in the rat. Twenty-four rats were housed in cages in which lighting was supplied between the hours of 0700 and 1900 daily. After 3 weeks of such treatment, groups of three animals were killed at intervals of 3 hr as indicated. Blood was collected, and the adrenal glands from the three animals were excised and pooled for homogenization. One gram portions of liver were also removed from each animal, pooled, and homogenized, and microsomal HMG CoA reductase was assayed as described previously (24) . Plasma cholesterol and corticosterone and adrenal enzyme activities were measured as described under Materials and Methods. All assays were performed in duplicate.
to restore the content of adrenal cholesteryl esters and to suppress adrenal HMG CoA reductase activity and cholesterol synthesis (1, 2) . The data in Fig. 4 show that with increasing doses of LDL the relative degrees of suppression of HMG CoA synthase and HMG CoA reductase were remarkably similar. On the other hand, the activities of acetoacetyl CoA thiolase and mevalonate kinase were unaffected by the LDL infusion.
Because of the known circadian rhythm in corticosterone secretion by the rat adrenal gland (22), we sought to determine whether a diurnal variation could be demonstrated in adrenal HMG CoA synthase and reductase activities. Accordingly, rats were exposed to a repetitive light-dark cycle for 3 weeks, and then groups of animals were killed at 3 hr intervals throughout a 24 hr cycle (Fig. 5) . Both adrenal HMG CoA synthase and reductase activities showed a diurnal rhythm with peak activities at about the mid-point of the dark cycle (Fig. 5C ). The rise in reductase appeared to slightly precede the rise in synthase activity. The peak in adrenal HMG CoA reductase activity coincided with the peak in liver HMG CoA reductase activity (Fig. SB) . Interestingly, in the adrenal gland the peaks in syn- The observation in the current studies of a diurnal variation in both HMG CoA synthase and reductase activities in adrenal gland provides additional evidence that these two enzymes are coordinately controlled. The peak activity of both enzymes occurred after the peak in plasma corticosterone levels. These data are consistent with the generally accepted view that the action of adrenocorticotropic hormone causes a cleavage of stored adrenal cholesteryl esters with rapid conversion of the liberated cholesterol to corticosterone (23) . Thus, the rise in activities of HMG CoA synthase and reductase that follows the adrenocorticotropic hormone-mediated burst of corticosterone secretion during the early dark phase of the diurnal cycle may represent a mechanism by which the adrenal gland replaces the cellular cholesterol that has been consumed for hormone synthesis. The maximal levels of HMG CoA synthase and reductase activities achieved during the diurnal cycle are much lower than the levels observed when the level of plasma cholesterol is reduced by This suggests that during the dark phase the adrenal gland not only synthesizes cholesterol but also takes up cholesterol from plasma lipoproteins, an action that keeps the activities of HMG CoA synthase and reductase partially suppressed. Consistent with this hypothesis was the observation that when 4-APP-treated rats were killed at 2100
